CORT
Corcept Therapeutics Incorporated
Biotechnology · Healthcare · United States
110.51
close · 2026-08-13
value
15
cheaper than peers15
quality
94
stronger fundamentals94
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 14.05× | 46 |
| forward P/E | 24.47× | 36 |
| price to book | 16.90× | 15 |
| EV to EBITDA | 1431.28× | 1 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.3% | 91 |
| operating margin | 16.1% | 79 |
| return on equity | 8.2% | 77 |
| revenue growth | 31.7% | 52 |
4 of 4 measures available
Facts
| market cap | $12B |
| free cash flow | $77.4M |
| employees | 730 |
| first trade | 2004-04-14 |
| next earnings | 2026-07-29 |
| fundamentals updated | 2026-08-06 |